All In Biotech

Drug Trial Radar · NCT06630884

Inflammatory Challenge and Fear

Inflammatory Challenge and Fear Extinction: A Model to Enhance Understanding of Posttraumatic Stress Disorder

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 288 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

288

Planned (sponsor's estimate)

Start

Mar 28, 2025

Primary completion

Nov 2028

Study completion Nov 2028

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Mental Health (NIMH); Northern California Institute of Research and Education; San Francisco Veterans Affairs Medical Center
First posted
Oct 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to learn if short-term changes in the immune system alter how we process information and experience fear. The main questions it aims to answer are: Do people who receive typhoid vaccine respond differently than those who receive a placebo saline vaccine? Do people who receive typhoid vaccine experience changes in how they think and feel? Participants will: Attend four appointments at the San Francisco VA Health Care System; Receive typhoid vaccine or placebo at one of the visits; Have their physiological responding measured while listening to sounds; Complete questionnaires and psychological tests.

Conditions

  • Posttraumatic Stress Disorder (PTSD)

Interventions

  • Typhoid VI Polysaccharide Vaccine Injectable SolutionBiological

    Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.

  • Saline Placebo (0.5mL injection)Other

    The placebo injection will consist of 0.5mL of saline.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Skin conductance response (SCR)Time frame: SCR will be assessed at baseline, 4.5 hours, and one week after vaccine/placebo.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • San Francisco VA Health Care System

    San Francisco, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.